There are currently 88 active clinical trials seeking participants for HIV Infections research studies. The states with the highest number of trials for Autism participants are California, New York, Florida and Texas.
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
NCT04985760
Recruiting
Trimer 4571 is a vaccine designed to stimulate the development of broadly neutralizing antibodies (bnAbs) against HIV. Trimer 4571 is investigational, meaning it is not approved by the US Food and Drug Administration (FDA). There is limited human experience with the Trimer 4571 vaccine administered with aluminum hydroxide (alum) and the vaccine has not been tested in people with HIV prior to this study although it has been tested in healthy volunteers. The goal of this study is to see if Trimer... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: AIDS Clinical Trials Unit/The Ohio State University, Columbus, Ohio +1 locations
Conditions: HIV Infections
Register for Updates
Exploring, Predicting, and Intervening on Long-term Viral Suppression Electronically
NCT06370780
Recruiting
Despite the widespread availability of effective antiretroviral therapy (ART) in the United States, there remains significant numbers of people living with HIV (PLWH) who fail to achieve and or maintain viral suppression (VS). Disparities persist with the lowest levels of VS among Black individuals, people who use drugs, youth ages 18-24 and people residing in rural areas. Investigators will examine the syndemics underlying these outcomes including substance use, mental health, and barriers to H... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: HIV Infections
Register for Updates
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05917509
Recruiting
This is a multicentre study carried out in participants living with human immunodeficiency virus type 1 (HIV-1) who have not previously been treated with any antiretroviral therapies. The study will investigate two 2-drug regimens for the treatment of HIV-1: a fixed-dose combination oral tablet of dolutegravir/lamivudine (DTG/3TC) and cabotegravir plus rilpivirine long-acting agents (CAB + RPV LA). All participants will initially receive DTG/3TC once daily, and once virologic suppression is atta... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: GSK Investigational Site, Birmingham, Alabama +56 locations
Conditions: HIV Infections
Register for Updates
An Electronic Health Record-based Approach to Increase PrEP Knowledge and Uptake: the EMC2 PrEP Strategy
NCT05709860
Recruiting
This study is being conducted to investigate a strategy that may improve knowledge and uptake of pre-exposure prophylaxis for HIV prevention (PrEP) among cisgender women in primary care.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: HIV Infections, Electronic Health Record, Primary Health Care
Register for Updates
Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention
NCT06005298
Recruiting
This randomized control trial study among Pre-exposure prophylactic users (PrEP) aims to learn and determine the efficacy of Screening, brief intervention, and referral to treatment (SBRIT) in reducing the risk of alcohol use. The main questions it aims to answer are: How alcohol use impacts the PrEP continuum and to understand how early intervention and treatment approach affects alcohol use and PrEP adherence. Investigate the effectiveness of the SBIRT intervention in preventing hazardous alc... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/22/2024
Locations: University of Louisville, Louisville, Kentucky
Conditions: Alcohol Use Disorder, Risk Behavior, Health, Dysbiosis, HIV Infections
Register for Updates
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
NCT05510908
Recruiting
This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in cancer clinical trials. Optional quality of life surveys will be used to learn more about how HIV and cancer and HIV and cancer treatment affect people.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Moores UCSD Cancer Center, La Jolla, California +10 locations
Conditions: HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma, AIDS-related Kaposi Sarcoma, AIDS-Related Malignancy, Anal Cancer, HPV-Related Malignancy
Register for Updates
Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men
NCT06205368
Recruiting
The goal of this clinical trial is to test the efficacy of a mobile app, Combine, to increase the uptake of HIV and STI testing and pre-exposure prophylaxis (PrEP) over 24 months and to assess the effects of different implementation strategies on intervention maintenance among GBMSM in rural southern United States. The main aims of the study are: To assess the relative effects of three treatment conditions on gains in engagement in HIV prevention compared to a modified standard of care control... Read More
Gender:
Male
Ages:
Between 18 years and 34 years
Trial Updated:
04/17/2024
Locations: Emory University, Atlanta, Georgia
Conditions: HIV Infections, STI, HIV Pre-exposure Prophylaxis
Register for Updates
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants
NCT06033547
Recruiting
The primary purpose of the study is to investigate the safety, tolerability, and pharmacokinetic (PK) profiles of two different cabotegravir formulations in healthy adult participants. The study will initially start with the assessment of Cabotegravir Formulation F. Once the clinical batch of Cabotegravir Formulation G is available, this formulation will be assessed.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/17/2024
Locations: GSK Investigational Site, Austin, Texas
Conditions: HIV Infections
Register for Updates
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
NCT05551273
Recruiting
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study will also evaluate if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/16/2024
Locations: Alabama CRS, Birmingham, Alabama +38 locations
Conditions: Hepatitis B, HIV Infections
Register for Updates
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
NCT05655546
Recruiting
The investigators will examine whether a combination of at-home nucleic acid amplification tests, on-demand telemedicine, and delivery of prescriptions such as Paxlovid quickly after testing positive for COVID-19, can reduce severe outcomes and hospitalization of immunocompromised patients and those who are 65 years and older. They will also analyze whether these efforts lower the cost of care compared to standard of care.
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/15/2024
Locations: Scripps Research, La Jolla, California
Conditions: Immunodeficiency, Immunosuppression, HIV Infections, Graft Versus Host Disease, Leukemia, Lymphoma, Cancer, Multiple Myeloma, Transplant, Age-Related Immunodeficiency
Register for Updates
Accelerated ART Initiation for PWHIV Who Are Out of Care
NCT06374758
Recruiting
The main purpose of the study is to evaluate the effectiveness, of the ACCELERATE model of care to achieve HIV viral suppression at Week 24. The study will also assess the acceptability, appropriateness, feasibility, and sustainability of the ACCELERATE model of care. The ACCELERATE model combines a standardized method for outreach, the use of telehealth for rapid access to an HIV care provider, a simplified pre-approved HIV regimen, a free 30-day medication starter supply, and re-linkage to med... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: University of Missouri-Columbia, Columbia, Missouri
Conditions: HIV Infections, ART, Noncompliance, Patient
Register for Updates
Expanding the Potential of Couples HIV Testing: Adjunct Modules to Reduce Drug Use Among Vulnerable Male Couples
NCT05000866
Recruiting
This study utilizes a randomized controlled trial design to evaluate the efficacy of two intervention components for couples HIV testing and counseling (CHTC): a communication skills training video and a substance use module. Participants are randomized in a full-factorial design to one of 4 conditions: CHTC as usual; CHTC + communication skills training videos; CHTC + substance use module; or CHTC plus both adjunct components.
Gender:
Male
Ages:
Between 17 years and 29 years
Trial Updated:
04/11/2024
Locations: University of Michigan, Ann Arbor, Michigan +1 locations
Conditions: Substance Use, HIV Infections
Register for Updates